Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
Denmark
Rigshospitalet, Copenhagen France
Centre Hospitalier Universitaire dÁngers, Angers CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology, Montpellier Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris, Paris Germany
Katholisches Klinikum Bochum, Bochum Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE), Bonn Universitatsklinikum Essen - Neurologie, Essen Universitatsklinikum Tübingen, Tübingen Israel
Meir Medical Center, Kfar Saba Sourmansky Medical Center, Tel Aviv Netherlands
Leiden University Medical Center LUMC, Leiden Radbout University Medical Centre, Nijmegen United Kingdom
University College London Hospitals NHS Foundation, London John Radcliffe Hospital, Oxford